Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore changes in subcutaneous adipose tissue and modulation of skin inflammation after 12 weeks of treatment with secukinumab, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult patients with moderate to severe plaque psoriasis (ObePso-S). CAIN457AUS07
Description The purpose of this research study is to find if the drug secukinumab (also called AIN457) has beneficial effects beyond skin inflammation in people who have moderate to severe plaque psoriasis.

Participants will be asked to remain in the study for about 12 - 13 months.

Study visits will be in downtown Buffalo at the Clinical Research Center (CRC) located within the University of Buffalo's Clinical Translational Research Center (CTRC).

If you're interested in this study, please contact the study contact listed below.
Objective Secukinumab targets interleukin 17a (IL-17a) which may play a critical role in the pathophysiology of psoriasis. IL-17 is not established as a factor in excess adiposity, however reports suggest that obesity may be a driver for the formation of TH17 T -cells. This study will provide a comparison of secukinumab to placebo with respect to skin inflammation as measured by skin exams in comparison to skin biopsies, adipose tissue and blood sample analyses. The primary objective of this study is to explore the modulation of subcutaneous adipose tissue and skin inflammation from baseline to Week 12 in patients with moderate to severe plaque psoriasis treated with secukinumab compared to placebo.

Keywords: plaque psoriasis
Principal Investigator SINHA, ANIMESH
Age Group Adult
Drugs Involved
Status Open
Key Eligibility 18 years of age and older
have a clinical diagnosis of plaque-type psoriasis
have moderate to severe plaque psoriasis
Disease Group Skin/Dermatology
Treatment Secukinumab (AIN457)
Contact Alba Posligua